Clinical Trial

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders.
Protocol Amendment History 21 amendments
This ClinicalTrials.gov record has been amended 21 times since 2025-07-29; most recent amendment 2026-07-20.
Status change: Not Yet Recruiting → Recruiting 2025-12-02
Trial Details
NCT Number NCT07104565
Lead Sponsor Incyte Corporation
Conditions Immune Thrombocytopenia
Enrollment 56 participants
Start Date 2025-12-29
Primary Completion 2027-09-23 (estimated)
Study Completion 2028-03-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-06